Evaluating Cancer Costs in NCI Trials

Publisher Website
Google Scholar
Abstract
Historically, the evaluation of new, therapeutic strategies for cancer have depended exclusively on safety and clinical efficacy. [1] Today, there is an increasing recognition by health care providers and financing organizations of the resource constraints on the provision of these services, lending greater importance to their economic evaluation. [1] – [4] Further, as costs for such services continue to rise, there is also a heightened desire for information on the value for each dollar spent in providing these technologies.